Endometrial Ca
72 programs · 68 companies
Programs
72
Companies
68
Trials
66
MOAs
44
GLP-1/GIPWEE1iJAK1/2iSOS1iCD47iSTINGagAuroraAiBTKiBETiTROP-2 ADC
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Phase 2/3 | TIGIT | ||
| MRK-853 | Phase 1 | PRMT5 | ||
| Fixanesiran | Preclinical | RET | ||
| Terarelsin | Preclinical | SOS1 | ||
| AZN-6294 | Phase 2/3 | APOC3 | ||
| SNY-4496 | Phase 2/3 | CD3 | ||
| TAK-5300 | Phase 1 | SMN2 | ||
| ARG-314 | Approved | Aβ | ||
| Sovanaritide | Phase 3 | TNFα | ||
| MDG-611 | Approved | CGRP | ||
| Surarasimod | Phase 2 | SHP2 | ||
| Pemitinib | Preclinical | BTK | ||
| RCU-2903 | NDA/BLA | EGFR | ||
| RAR-1117 | Phase 1/2 | TYK2 | ||
| Rimainavolisib | Phase 2 | C5 | ||
| EDI-3618 | NDA/BLA | FXIa | ||
| SLD-2973 | NDA/BLA | KIF18A | ||
| CSL-7919 | Preclinical | BTK | ||
| Nidatapinarof | Phase 2 | Cl18.2 | ||
| Capitapinarof | Preclinical | RET | ||
| FRE-IIT-954 | Phase 2/3 | FGFR | ||
| Elraratamab | Phase 1 | PCSK9 | ||
| Teratenlimab | Preclinical | JAK2 | ||
| INO-9184 | Phase 2/3 | CD3 | ||
| Polamavacamten | Phase 2 | LAG-3 | ||
| Elraderotide | NDA/BLA | SMN2 | ||
| Tiralucimab | Phase 2 | TNFα | ||
| PBY-3950 | Phase 2 | FGFR | ||
| Lisozanubrutinib | Approved | EGFR | ||
| Ivocapivasertib | Phase 1 | FLT3 | ||
| AMP-408 | Phase 1/2 | AuroraA | ||
| Bemarelsin | NDA/BLA | CD123 | ||
| Niracilimab | Phase 3 | CD19 | ||
| Cevitapinarof | Phase 2/3 | GIP-R | ||
| 117-9336 | Phase 2/3 | PLK4 | ||
| 000-7991 | Phase 1 | FXIa | ||
| Tiratinib | Preclinical | FLT3 | ||
| RYT-9424 | Phase 2/3 | CGRP | ||
| Zenovorutinib | Preclinical | Cl18.2 | ||
| Semaglumide | Phase 3 | SGLT2 | ||
| TAI-4908 | Phase 3 | Menin | ||
| RNA-7525 | Phase 2/3 | TYK2 | ||
| MRK-9679 | NDA/BLA | Menin | ||
| Fixacagene | Approved | GLP-1R | ||
| Zanurapivir | Phase 2 | CD47 | ||
| EXA-3015 | Phase 1 | APOC3 | ||
| Daracilimab | Preclinical | TNFα | ||
| MOL-8666 | Approved | WEE1 | ||
| POL-2929 | Phase 2/3 | GPRC5D | ||
| CYA-8318 | Preclinical | MET | ||
| Elrabrutinib | Phase 3 | BCMA | ||
| MIR-8412 | Phase 1/2 | APOC3 | ||
| Sovasacituzumab | Phase 2 | TIM-3 | ||
| Lisozumab | Phase 2/3 | Menin | ||
| Suracagene | Phase 3 | BCMA | ||
| AJA-5085 | Preclinical | TIGIT | ||
| LUP-4095 | Phase 2/3 | Tau | ||
| Tiranesiran | Preclinical | MALT1 | ||
| Rilusotorasib | Preclinical | PLK4 | ||
| BIO-IIT-307 | Phase 2/3 | CFTR | ||
| Tixacilimab | Phase 2/3 | CD3 | ||
| KIN-IIT-636 | Phase 3 | KRASG12D | ||
| CTT-403 | Phase 1 | JAK2 | ||
| RGE-6554 | Phase 1 | SMN2 | ||
| BRK-7538 | Phase 2/3 | DLL3 | ||
| BRK-679 | Approved | PRMT5 | ||
| Sotozanubrutinib | Phase 2/3 | APOC3 | ||
| ACG-4705 | NDA/BLA | BET | ||
| Kemaderotide | Approved | AuroraA | ||
| Teracapivasertib | Phase 2/3 | IL-13 | ||
| Gelibrutinib | NDA/BLA | WRN | ||
| Fixaratamab | Approved | TYK2 |
Trials (66)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04836138 | Zanuderotide | Phase 2/3 | Completed |
| NCT06912054 | MRK-853 | Phase 1 | Recruiting |
| NCT08457379 | Fixanesiran | Preclinical | Active |
| NCT03575505 | Fixanesiran | Preclinical | Recruiting |
| NCT03535533 | ARG-314 | Approved | Completed |
| NCT07605100 | ARG-314 | Approved | Completed |
| NCT07054108 | MDG-611 | Approved | Not yet recr... |
| NCT03237085 | Pemitinib | Preclinical | Completed |
| NCT06905735 | RAR-1117 | Phase 1/2 | Recruiting |
| NCT04366048 | RAR-1117 | Phase 1/2 | Terminated |
| NCT05575955 | Rimainavolisib | Phase 2 | Recruiting |
| NCT08654436 | Rimainavolisib | Phase 2 | Terminated |
| NCT06508629 | EDI-3618 | NDA/BLA | Active |
| NCT06397924 | SLD-2973 | NDA/BLA | Not yet recr... |
| NCT04071077 | CSL-7919 | Preclinical | Completed |
| NCT03948626 | CSL-7919 | Preclinical | Completed |
| NCT04792628 | FRE-IIT-954 | Phase 2/3 | Completed |
| NCT03081841 | INO-9184 | Phase 2/3 | Not yet recr... |
| NCT06343050 | Polamavacamten | Phase 2 | Recruiting |
| NCT04634100 | Polamavacamten | Phase 2 | Completed |